These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27195088)

  • 1. Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Naseripour M; Falavarjani KG; Sedaghat A; Moghaddam AK; Nasserisina S; Alemzadeh SA
    J Ophthalmic Vis Res; 2016; 11(1):66-9. PubMed ID: 27195088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
    Li L; Yuan F; Xu GZ; Wang WJ
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
    PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Liu CF; Chen LJ; Tsai SH; Lai CC; Chan WC; Wu WC; Wang NK; Chen KJ; Hwang YS; Chen YP; Yeung L
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):400-5. PubMed ID: 24597844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Alkin Z; Perente I; Ozkaya A; Alp D; Agca A; Aygit ED; Korkmaz S; Yazici AT; Demirok A
    Clin Ophthalmol; 2014; 8():685-90. PubMed ID: 24741287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central serous chorioretinopathy.
    Jirarattanasopa P; Ratanasukon M; Bhurayanontachai P
    J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S56-60. PubMed ID: 22696853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
    Chan WM; Lai TY; Lai RY; Liu DT; Lam DS
    Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.
    Sakalar YB; Keklikci U; Unlu K; Alakus MF; Kara IH
    Curr Ther Res Clin Exp; 2010 Jun; 71(3):173-85. PubMed ID: 24683263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M; Zoli D; Musolino M; Traverso CE
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Noh SR; Kang MS; Kim K; Kim ES; Yu SY
    Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-time photodynamic therapy for central serous chorioretinopathy.
    Tsai MJ; Hsieh YT
    Optom Vis Sci; 2014 Sep; 91(9):1140-5. PubMed ID: 25083838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.